- Home
- NKTX vs BMEA Comparison
NKTX vs BMEA Comparison
Compare NKTX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- BMEA
- Stock Information
- Founded
- NKTX 2015
- BMEA 2017
- Country
- NKTX United States
- BMEA United States
- Employees
- NKTX N/A
- BMEA N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- BMEA Health Care
- Exchange
- NKTX Nasdaq
- BMEA Nasdaq
- Market Cap
- NKTX 123.5M
- BMEA 125.0M
- IPO Year
- NKTX 2020
- BMEA 2021
- Fundamental
- Price
- NKTX $2.30
- BMEA $1.51
- Analyst Decision
- NKTX Strong Buy
- BMEA Strong Buy
- Analyst Count
- NKTX 5
- BMEA 8
- Target Price
- NKTX $13.50
- BMEA $10.63
- AVG Volume (30 Days)
- NKTX 1.2M
- BMEA 3.2M
- Earning Date
- NKTX 11-06-2025
- BMEA 10-29-2025
- Dividend Yield
- NKTX N/A
- BMEA N/A
- EPS Growth
- NKTX N/A
- BMEA N/A
- EPS
- NKTX N/A
- BMEA N/A
- Revenue
- NKTX N/A
- BMEA N/A
- Revenue This Year
- NKTX N/A
- BMEA N/A
- Revenue Next Year
- NKTX N/A
- BMEA N/A
- P/E Ratio
- NKTX N/A
- BMEA N/A
- Revenue Growth
- NKTX N/A
- BMEA N/A
- 52 Week Low
- NKTX $1.31
- BMEA $1.29
- 52 Week High
- NKTX $4.55
- BMEA $12.85
- Technical
- Relative Strength Index (RSI)
- NKTX 53.68
- BMEA 37.61
- Support Level
- NKTX $2.11
- BMEA $1.57
- Resistance Level
- NKTX $2.74
- BMEA $1.71
- Average True Range (ATR)
- NKTX 0.18
- BMEA 0.19
- MACD
- NKTX 0.03
- BMEA -0.06
- Stochastic Oscillator
- NKTX 39.58
- BMEA 3.88
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.